JAK2 and acute lymphoblastic leukemia: Similar to TKIs, all clinically available JAK2 inhibitors are ATP mimetics and there are concerns that incorporation of JAK2 inhibitors into treatment approaches for JAK2r ALL will lead to the development of resistance (Miller et al., 2014; Meyer, 2017).